Pathology Core

病理学核心

• 批准号: 10696165
• 负责人: Bart O Williams
• 金额: $ 21.51万
• 依托单位: CORIELL INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-16 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10696165
• 关键词: AML/MDS; Aftercare; Animal Model; Biological Assay; Biological Markers; Biological Process; Biological Specimen database; Biopsy; Blood; Bone Marrow; Bone Tissue; Cell Count; Cell Line; Cells; Clinical; Clinical Data; Clinical Trials; Collaborations; Collection; Communities; DNA; DNA Methylation; Data; Databases; EZH2 gene; Endogenous Retroviruses; Epigenetic Process; Evaluation; Flow Cytometry; Gene Expression; Generations; Genomics; Goals; Histology; Image; Immune; Immunohistochemistry; Immunologic Markers; Immunologic Monitoring; Immunophenotyping; Indiana; Institution; Label; Laboratories; Location; Malignant Neoplasms; Maryland; Measures; Methylation; Monitor; Nucleic Acids; Participant; Pathologic; Pathology; Patients; Phenotype; Principal Investigator; Procedures; Process; RNA; Randomized; Refractory; Relapse; Research; Research Personnel; Research Project Grants; Research Support; Resources; Sampling; Science; Serum; Services; Site; Specimen; T-Lymphocyte; Technology; Testing; Time; Tissue Microarray; Tissues; Universities; bead chip; biobank; brca gene; clinical trial protocol; cohort; digital imaging; efficacy evaluation; epigenetic therapy; exhaustion; image archival system; insight; novel therapeutic intervention; performance site; peripheral blood; prospective; repository; therapeutic evaluation; transcriptome; treatment response; tumor

Abstract Pathology/Biospecimen/Biorepository Core (PBC) The PBC will manage the collection of patient-derived biospecimens from blood, bone marrow and tissue (cancer and normal) as determined by the trial parameters often with collections occurring at pre and post treatment time points to meet the research aims of the proposed SPORE projects. The PBC Core will provide collection materials, specimen labels and manage shipments of biospecimens to VAI. The specimen derivatives will be distributed to the locations for assay performance site including the SPORE’s Genomics Core and other collaborating project investigators. Pathology-based histology assessment, DNA methylation EPIC BeadChip arrays and immunophenotype monitoring will be provided by the PBC Core. The PBC Core will assess and maintain excellent quality in the collection of biospecimens for use in the correlative science research that are used to determine efficacy, biological function and mechanistic details for the evaluation of the therapeutic treatments and scientific goals of the SPORE projects. For Project 1, the Core will collect process and store peripheral blood and bone marrow samples related to a randomized study of MC180295+Atezolizumab, MC180295+DAC and MC180295+DAC+Atezolizumab in relapsed or refractory AML/MDS. Biospecimens collected will be managed by the PBC Core with nucleic acids being sent to the Genomics Core for assessment of epigenetic parameters. Immune cell parameters (cell numbers, gene expression in T-cells, T-cell exhaustion parameters) will be measured in the PBC Flow Cytometry Core. Approximately 600 data points will be assayed from this cohort. For Project 2, the Core will collect samples from the clinical trial of combined DNMT and EZH1/2 inhibition that is planned to begin in year 2 with collection and management of peripheral blood and tumor biopsies pre and post therapy to assess epigenetic modulation and biomarkers (done in the Genomics Core) and Immune biomarkers (done in the PBC Core). Approximately 1,400 data points are expected from this cohort. Project 3 will use the PBC Core resources to collect and manage pre and post therapy biospecimens and to provide specimen DNA and RNA derivatives to the Genomic Core for BRCAness gene expression, DNA methylation and global gene expression including ERVs. The PBC Core’s access to the VAI Flow Cytometry Core will provide immune monitoring and the PBC Core’s access to the VAI Genomics Core will provide the Methylation EPIC BeadChip array for evaluation. Approximately 640 to 800 specimens will be tested to meet the aims of this project. The Pathology and Biospecimen Core will provide access and distribution of project specimens to downstream assay sites, whether they are within the Core Technologies at VAI, the Genomics Core at Coriell, principal investigators laboratories or other approve investigators beyond the principal SPORE investigators.

摘要病理学/生物质学/生物信息库核心(PBC) PBC将管理从血液、骨髓和组织(癌症)中收集患者来源的生物标本 和正常)由试验参数确定，通常在治疗前和治疗后时间进行收集 达到拟议孢子项目的研究目标的点数。中国人民银行将提供收藏品 材料、标本标签和向VAI发运生物标本的管理。样本衍生品将是 分布到包括孢子的基因组核心和其他检测表现部位的位置 合作的项目调查人员。DNA甲基化EPIC珠芯片的病理组织学评估 阵列和免疫表型监测将由PBC核心提供。PBC核心将评估和 保持高质量的生物标本收集，用于相关的科学研究 用于确定疗效、生物功能和机制细节，以评估治疗 孢子项目的治疗方法和科学目标。对于项目1，核心将收集、处理和存储 与MC180295+Atezolizumab随机研究有关的外周血和骨髓样本， MC180295+DAC和MC180295+DAC+Atezolizumab治疗复发或难治性AML/MDS生物旋毛虫 收集的数据将由PBC核心管理，核酸将被送到基因组核心进行评估 表观遗传参数。免疫细胞参数(细胞数量、T细胞基因表达、T细胞耗竭 参数)将在PBC流式细胞仪核心中进行测量。将分析大约600个数据点 来自这群人。对于项目2，核心将从DNMT和EZH1/2联合临床试验中收集样本 计划在第二年开始抑制，收集和管理外周血和肿瘤 治疗前后的活组织检查以评估表观遗传调节和生物标记物(在基因组学核心中完成) 和免疫生物标记物(在PBC核心中完成)。预计这一队列中将有大约1400个数据点。 项目3将使用建设和平委员会的核心资源来收集和管理治疗前和治疗后的生物标本，并 为BRCAness基因表达的基因组核心提供样本DNA和RNA衍生物 甲基化和包括ERV在内的全球基因表达。PBC核心对VAI流式细胞术的访问 核心将提供免疫监测，而PBC核心对VAI基因组核心的访问将提供 用于评估的甲基化EPIC珠片阵列。将对大约640至800个样本进行测试，以满足 这个项目的目标。病理学和生物学家核心将提供项目的访问和分发 样本到下游化验地点，无论它们是在VAI的核心技术，基因组学 科里尔中心、首席调查员实验室或主孢子以外的其他认可调查员 调查人员。